SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00055848

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Familial Factors in the Development of Colon Cancer

RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Clinical trial to study the cancer-related genes in patients who have colon cancer or adenomatous polyps.

NCT00055848 Colorectal Cancer
MeSH:Colonic Neoplasms
HPO:Colon cancer Neoplasm of the colon

3 Interventions

Name: cytogenetic analysis

Type: Genetic
Group Labels: 1

Group 1

Name: gene mapping

Type: Genetic
Group Labels: 1

Group 1

Name: microarray analysis

Type: Genetic
Group Labels: 1

Group 1



Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 I1370K

DISEASE CHARACTERISTICS: - Diagnosis of colon cancer or polyps at age 70 or under - Has a living full sibling with diagnosis of colon cancer or polyps at age 70 or under - No history of familial adenomatous polyposis syndrome - No hereditary nonpolyposis colon cancer, according to Amsterdam criteria - No known I1370K adenomatous polyposis of the colon susceptibility variant - Enrolled on 1 of the following clinical trials: - CLB-9581 - CLB-89803 - CLB-80001 NOTE: Patients do not need to be receiving protocol therapy. --- I1370K ---

PATIENT CHARACTERISTICS: Age - 70 and under at diagnosis Other - No significant psychiatric illness that would preclude giving informed consent - No inflammatory bowel disease (in patient or sibling) DISEASE CHARACTERISTICS: - Diagnosis of colon cancer or polyps at age 70 or under - Has a living full sibling with diagnosis of colon cancer or polyps at age 70 or under - No history of familial adenomatous polyposis syndrome - No hereditary nonpolyposis colon cancer, according to Amsterdam criteria - No known I1370K adenomatous polyposis of the colon susceptibility variant - Enrolled on 1 of the following clinical trials: - CLB-9581 - CLB-89803 - CLB-80001 NOTE: Patients do not need to be receiving protocol therapy. --- I1370K ---



HPO Nodes


HPO: